Top 10 itm-radiopharma.com Competitors

relmada.com

CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”),…...

immunocore.com

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. Our mission is to radically improve outcomes for patients with cancer,…

nanobiotix.com

Laurent Lévy is the Cofounder of Nanobiotix and has served as Chief Executive Officer since 2003. He was first appointed as Chairman of the Executive Board on May 27, 2004. Laurent has extensive experience in the sciences and techniques related to nanotechnology. Prior to founding Nanobiotix, Laurent served as a consultant for Altran Technologies and worked in the development of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., Rhodia S.A., and other early-stage biotechnology companies. He served as President of the Supervisory Board of Valbiotis S.A. (Euronext Paris: ALVAL), was Vice Chairman of the Executive Board of the European Technology Platform on Nanomedicine (ETPN), and was a founding member of the Nanomedicine Translation Advisory Board (a division of ETPN). Laurent has authored more than 35 scientific publications, has applied for and secured several patents, and regularly speaks on the topic of using nanoparticles to fight cancer and other diseases. He holds a doctorate in physical chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie; UPVI-ESPCI) in Paris and from the Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA), and a DEA (advanced studies and diplomas) in physics of condensed matter from the UPVI-ESPCI. Laurent completed his studies with a postdoctoral fellowship at the Institute for Lasers, Photonics and Biophotonics at the State University of New York at Buffalo (SUNY Buffalo).

viridiantherapeutics.com

WALTHAM, Mass.–(BUSINESS WIRE)– Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering,Read More

alector.com

All candidate activity and open positions are managed strictly through our Talent Acquisition department.

celcuity.com

Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway.

neurimmune.com

Beschreibung für das Impressum

tectonictx.com

Tectonic is a biotechnology company focused on the discovery and development of proteins and antibodies that modulate the activity of G-Protein Coupled Receptors.

txbiomed.org

Listen to the TXBioBytes podcast from Texas Biomed.